3 December 2020 in Journal of Drug Targeting
MKMohammad Reza Khirehgesh
Targeted therapy is one of the favorable methods used in cancer treatment. Several recombinant proteins and small-molecules such as monoclonal antibodies, antibody fragments, and peptides are used to this aim. Nanobody is a camelid antibody fragment that is very effective in targeted therapy. Recently, several anti- EGFR (epidermal growth factor receptor) nanobodies have been developed and utilized for diagnosis and therapy of EGFR overexpressing tumors. Anti- EGFR nanobodies used in drug delivery systems, photodynamic therapy (PDT) and/or conjugated to other molecules such as quantum dots (QDs), nanoparticles, liposome, tumor penetration peptides, neural stem cells (NSC), and chimeric antigen receptor T cells (CART cells). In this review, we discuss the structure and function of EGFR and nanobody, the current status of EGFR targeting, and recent developments in anti- EGFR nanobodies. To gain sound insight into the issue at hand, we focus on the most powerful anti- EGFR nanobodies.
8 March 2021 in Journal of Drug Targeting
MKMohammad Reza Khirehgesh
Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively. ITs have been successful in haematologic malignancies treatment. However, ITs penetrate poorly into solid tumours because of their large size. Use of camelid antibody fragments known as nanobodies (Nbs) as a targeting moiety may overcome this problem. Nbs are the smallest fragment of antibodies with excellent tumour tissue penetration. The ability to recognise cryptic (immuno-evasive) target antigens, low immunogenicity, and high-affinity are other fundamental characteristics of Nbs that make them suitable candidates in targeted therapy. Here, we reviewed and discussed the structure and function of ITs, Nbs, and nanobody-based ITs. To gain sound insight into the issue at hand, we focussed on nanobody-based ITs.
1 December 2021 in Journal of Drug Delivery Science and Technology
MKMohammad Reza Khirehgesh
+1